The two independent and NN^ coordination sites of a newly synthesized bis2‐(hydroxyphenyl)‐1,2,4‐triazole platform have been exploited to prepare four monometallic neutral ()PtII complexes carrying DMSO, pyridine, triphenylphosphine, or N‐heterocyclic carbene as the fourth ligand. Then, the second NN^ coordination site was used to introduce an IR‐active rhenium tricarbonyl entity, affording the four corresponding heterobimetallic neutral PtII/ReI complexes, as well as a cationic PtII/ReI derivative. X‐ray crystallographic studies showed that distortion of the organic platform occurred to accommodate the coordination geometry of both metal centers. No ligand exchange or transchelation occurred upon incubation of the PtII complexes in aqueous environment or in the presence of FeIII, respectively. The antiproliferative activity of the ligand and complexes was first screened on the triple‐negative breast cancer cell line MDA‐MB‐231. Then, the IC50 values of the most active candidates were determined on a wider panel of human cancer cells (MDA‐MB‐231, MCF‐7, and A2780), as well as on a nontumorigenic cell line (MCF‐10A). Low micromolar activities were reached for the complexes carrying a DMSO ligand, making them the first examples of highly active, but hydrolytically stable, PtII complexes. Finally, the characteristic mid‐IR signature of the {Re(CO)3} fragment in the Pt/Re heterobimetallic complexes was used to quantify their uptake in breast cancer cells. Pt/Re anticancer agents: The development of heterobimetallic PtII/ReI complexes offers tools for the optimization of the anticancer properties of a new PtII scaffold bearing an pincer ligand associated with a monodentate ligand.